Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cisbio, BellBrook ink distribution agreement
January 2013
SHARING OPTIONS:

CODOLET, France—A global distribution agreement was established in November between Cisbio Bioassays and BellBrook Labs for the latter's Transcreener EPIGEN Methyltransferase assay. Per the terms of the agreement, Cisbio will offer the tool for epigenetic drug discovery studies to pharmaceutical and biotechnology researchers in the United States, Europe and Asia. Financial details were not disclosed. Transcreener EPIGEN Methyltransferase is a fluorescence polarization-based tool based on Transcreener AMP/GMP assay technology, and offers researchers sensitivity for detecting enzyme function as well as necessary technical aspects for high-throughput screening. Bob Lowery, CEO of BellBrook Labs, said in a press release that they are "excited to partner with Cisbio Bioassays in order to make our Transcreener EPIGEN technology available to a greater number of researchers involved in such a vital field of study."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.